Cloning and expression of the fusion protein of interleukin-2 and ESAT6 in Mycobacterium bovis Bacillus Calmette Guérin strain  

作　　者：FANXiong-lin WANGLi-mei LUXian-yu TUZhi-guang SHIChang-hong XUZhi-kai 

机构地区：[1]DepartmentofMicrobiology,FourthMilitaryMedicalUniversity,Xi＇an710032,China [2]DepartmentofPathogenicBiology,TongjiMedicalCollege,HuazhongUniversityofScienceandTechnology,Wuhan430030,China [3]DepartmentofClinicalImmunology,ChongqingUniversityofMedicalScience,Chongqing400016,China

出　　处：《Chinese Medical Journal》2005年第9期762-765,共4页中华医学杂志（英文版）

基　　金：ThisworkwassupportedbygrantsfromNationalNaturalScienceFoundationofChina(No. 30170855 ) and863 ProjectProgram(No. 2001AA215201)

摘　　要：Tuberculosis (TB) is the most common cause of death in infectious diseases; it is estimated that approximately 2 million people per year die of TB. The present available TB vaccine is a live attenuated strain, Mycobacterium bovis Bacillus Calmette Guérin (BCG). However, it has been shown that BCG has variable protective efficacy, ranging from 0 to 85% in different clinical experiments. 1 Therefore, a new TB vaccine is urgently needed. Many trials have been done to develop the second-generation TB vaccines in recent years; candidates include avirulent, auxotrophic, subunit, DNA, and recombinant vaccines. 2 The outcomes of these vaccines disappointed investigators. Encouragingly, recombinant BCG, which overexpressed the mycobacterial antigen Ag85B, produced an excellent protective response, 3,4 suggesting that a vaccine based on recombinant BCG technique was a potential approach against TB.Tuberculosis (TB) is the most common cause of death in infectious diseases; it is estimated that approximately 2 million people per year die of TB. The present available TB vaccine is a live attenuated strain, Mycobacterium bovis Bacillus Calmette Guérin (BCG). However, it has been shown that BCG has variable protective efficacy, ranging from 0 to 85% in different clinical experiments. 1 Therefore, a new TB vaccine is urgently needed. Many trials have been done to develop the second-generation TB vaccines in recent years; candidates include avirulent, auxotrophic, subunit, DNA, and recombinant vaccines. 2 The outcomes of these vaccines disappointed investigators. Encouragingly, recombinant BCG, which overexpressed the mycobacterial antigen Ag85B, produced an excellent protective response, 3,4 suggesting that a vaccine based on recombinant BCG technique was a potential approach against TB.

关 键 词：Mycobacterium tuberculosis INTERLEUKIN-2 VACCINE Bacillus Calmette Guérin ESAT6 

分 类 号：R515[医药卫生—内科学]